Tofacitinib
Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 67 - 69 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.64715 İndeks Tarihi: 18-07-2022
Tofacitinib
Öz: Tofacitinib is an oral inhibitor of janus kinases, which is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ulcerative
colitis in adults; its efficacy in the treatment of psoriasis has also been demonstrated in clinical studies. A 10 mg daily dose has been observed
to achieve a PASI75 response in 40-64% of the patients with moderate to severe psoriasis at week 12 or 16. It provides advantage in the
treatment of psoriasis due to oral use, lower cost compared to other biologics, and absence of organ toxicity.
Anahtar Kelime: Tofasitinib
Öz: Yetişkinlerde romatoid artrit, psoriatik artrit ve ülseratif kolit tedavisi için onaylı oral janus kinaz inhibitörü olan tofasitinibin psoriasis tedavisinde
de etkinliği klinik çalışmalarda gösterilmiştir. Günlük 10 mg dozda orta ve şiddetli psoriasisde 12 veya 16 haftalarda hastaların %40-64’ünde
PAŞİ75 yanıtına ulaşıldığı gözlenmiştir. Oral kullanılması, diğer biyolojiklere göre düşük maliyeti ve organ toksisitesinin olmaması ile psoriasis
tedavisinde avantaj sağlamaktadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Tian F, Chen Z, Xu T: Efficacy and safety of tofacitinib for the treatment of chronic plaque psoriasis: A systematic review and meta-analysis. J Int Med Res 2019;47:2342-50.
- 2. Azevedo A. Torres T: Tofacitinib: A new oral therapy for psoriasis. Clin Drug Investig 2018;38:101-12.
- 3. Ghoreschi K, Laurence A, O’Shea JJ: Janus kinases in immunecell signaling. Immunol Rev 2009;228:273-87.
- 4. Karaman MW, Herrgard S, Treiber DK, et al.: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
- 5. Krueger J, Clark JD, Suárez-Fariñas M, et al.: Tofacitinib attenuates pathologic immune pathways in patients with psoriasis:a randomized phase 2 study. J Allergy Clin Immunol 2016;137:1079-90.
- 6. Ghoreschi K, Jesson MI, Li X, et al.: Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186:4234- 43.
- 7. Borie DC, O’Shea JJ, Changelian PS: JAK3 inhibition, a viable new modality of immunosuppression for solid organ transplants. Trends Mol Med 2004;10:532-41.
- 8. Strober B, Buonanno M, Clark JD, et al.: Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. Br J Dermatol 2013;169:992-9.
- 9. Gelfand JM, Armstrong AW, Bell S, et al.: National Psoriasis Foundation COVID-19 task force guidance for management of psoriatic disease during the pandemic: Version 1. J Am Acad Dermatol 2020;83:1704-16.
- 10. Papp KA, Menter A, Strober B, et al.: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012;167:668-77.
- 11. Mamolo C, Harness J, Tan H, Menter A: Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a Phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 2014;28:192- 203.
- 12. Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M: Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderateto-severe plaque psoriasis in different body regions. J Drugs Dermatol 2014;13:252-6.
- 13. Bachelez H, van de Kerkhof PC, Strohal R, et al.: Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a Phase 3 randomised non-inferiority trial. Lancet 2015;386:552-61.
- 14. Hutmacher MM, Papp K, Krishnaswami S, et al.: Evaluating dosage optimality for tofacitinib, an oral janus kinase inhibitor, in plaque psoriasis, and the influence of body weight. CPT Pharmacomet Syst Pharmacol 2017;6:322- 30.
- 15. XELJANZ_ (tofacitinib) [package insert]: Pfizer Laboratories Div Pfizer Inc.; NY, NY; 2015. Available from: http://labeling.pfizer.com/ShowLabeling. aspx?id=959
- 16. Di Lernia V, Bardazzi F: Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis. Drug Des Dev Ther 2016;10:533-9.
- 17. Chiricozzi A, Faleri S, Saraceno R, et al.: Tofacitinib for the treatment of moderate-tosevere psoriasis. Expert Rev Clin Immunol 2015;11:443-55.
- 18. Asahina A, Etoh T, Igarashi A, et al.: Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, Phase 3 study. J Dermatol 2016;43:869-80.
- 19. Kim J, Tomalin L, Lee J, et al.: Reduction of inflammatory and cardiovascular proteins in the blood of psoriasis patients; differential responses between tofacitinib and etanercept after 4 weeks of treatment. J Investig Dermatol 2018;138:273-81.
- 20. Fleming P, Roubille C, Richer V, et al.: Effect of biologics on depressive symptomsin patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015;29:1063-70.
| APA | senturk n (2022). Tofacitinib . , 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| Chicago | senturk nilgun Tofacitinib . (2022): 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| MLA | senturk nilgun Tofacitinib . , 2022, ss.67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| AMA | senturk n Tofacitinib . . 2022; 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| Vancouver | senturk n Tofacitinib . . 2022; 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| IEEE | senturk n "Tofacitinib ." , ss.67 - 69, 2022. 10.4274/turkderm.galenos.2022.64715 |
| ISNAD | senturk, nilgun. "Tofacitinib ". (2022), 67-69. https://doi.org/10.4274/turkderm.galenos.2022.64715 |
| APA | senturk n (2022). Tofacitinib . Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| Chicago | senturk nilgun Tofacitinib . Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| MLA | senturk nilgun Tofacitinib . Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| AMA | senturk n Tofacitinib . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| Vancouver | senturk n Tofacitinib . Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 67 - 69. 10.4274/turkderm.galenos.2022.64715 |
| IEEE | senturk n "Tofacitinib ." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.67 - 69, 2022. 10.4274/turkderm.galenos.2022.64715 |
| ISNAD | senturk, nilgun. "Tofacitinib ". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 67-69. https://doi.org/10.4274/turkderm.galenos.2022.64715 |
